Oculis Holding (OCS) said Thursday that it has completed enrollment in two late-stage trials of OCS-01 eye drops in diabetic macular edema.
The trials, which enrolled more than 800 patients from the US and other countries, will assess the eye drops' efficacy and safety after 52 weeks of treatment, the company said.
The company said topline data from both trials is expected in Q2 of next year, followed by the submission of a new drug application.
Oculis shares were up 5.7% in recent premarket activity Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。